TrialCancer immunology, immunotherapy : CII2011
Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™.
Theo Nicholaou et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
21 papers cite it
this papertrialcites it